View of Clinical characteristics, re-infection, seropositivity and the role of Disease Modifying Drugs (DMDs) in COVID19 infected MS and NMOSD patients: A 12 months prospective observational study

Return to Article Details Clinical characteristics, re-infection, seropositivity and the role of Disease Modifying Drugs (DMDs) in COVID19 infected MS and NMOSD patients: A 12 months prospective observational study Download Download PDF